Interleukin‐6 Inhibitor, Tocolizumab, for COVID‐19: evidence review of the clinical benefit and harm

Parrish, A.Gray, A. Kredo, T. Maartens, G. Reubenson, G.Cohen, K.De Waal, R.Blockman, M.Nel, J.Rees, H.2020-07-202020-07-202020-04-15https://infospace.mrc.ac.za/handle/11288/595270enAttribution 3.0 United Stateshttp://creativecommons.org/licenses/by/3.0/us/Interleukin‐6 Inhibitor, Tocolizumab, for COVID‐19: evidence review of the clinical benefit and harmOther